The BCL2L1 Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting BCL2L1 in the A2780 human ovarian carcinoma cell line. This product consists of a heterogeneous pool of cells carrying targeted gene disruptions, generated via CRISPR/Cas9-mediated gene disruption without prior clone selection. The polyclonal format preserves genetic diversity and is suited for experiments requiring bulk gene ablation effects. This knockout model enables detailed investigation of BCL2L1-dependent antiapoptotic mechanisms in cancer cell survival.
The host cell line, A2780, is a widely used epithelial ovarian cancer model derived from an endometrioid adenocarcinoma of a treatment-na?ve patient. A2780 cells exhibit epithelial morphology, wild-type TP53 status, and sensitivity to platinum-based agents and taxanes, making them ideal for drug sensitivity and apoptosis studies. This ovarian carcinoma background provides a relevant context for probing BCL2L1 function.
BCL2L1 encodes Bcl-xL, an antiapoptotic protein that binds and inhibits proapoptotic BAX and BAK, blocking mitochondrial outer membrane permeabilization and cytochrome c release. Bcl-xL is activated by PI3K/AKT, JAK/STAT, and NF-??B signaling, with upstream mediators IL-3, EPO, STAT3, and RelA/p65. Knockout of BCL2L1 unleashes BH3-only proteins BIM, PUMA, and BAD to trigger BAX/BAK oligomerization, apoptosome formation via APAF1, and caspase-9/3 activation. Bcl-xL also interacts with VDAC and modulates both intrinsic and extrinsic apoptotic pathways.
Overexpression of Bcl-xL is frequently associated with chemoresistance in ovarian cancer; thus, knockout of BCL2L1 in A2780 cells provides a physiologically relevant model for studying apoptotic sensitization. Loss of Bcl-xL enhances sensitivity to chemotherapeutics such as cisplatin and paclitaxel and may uncover synthetic lethal interactions. This polyclonal knockout model enables detailed dissection of Bcl-xL??s contribution to mitochondrial apoptosis and drug response in an epithelial cancer setting.
These BCL2L1 knockout polyclonal cells are suitable for apoptosis assays (Annexin V/propidium iodide flow cytometry), cell viability (MTT, ATP), cytochrome c release, caspase-3/9 activity measurements, western blotting, colony formation, and BH3 profiling. They also support drug sensitivity screens with cisplatin or paclitaxel and synthetic lethality studies. For further technical information, please contact Ascent Research.
